Biom Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for brain disorders. Our mission is to improve human health and quality of life by developing innovative drugs for treating and possibly reversing the effects of hard-to-treat diseases such as rare epilepsies, Alzheimer’s disease and Autism. Biom’s initial focus is on rare pediatric epilepsy such as developmental and epileptic encephalopathies and Angelman syndrome. Dr. Paul Carney, a tenured professor at Missouri University’s School of Medicine, is a board-certified pediatric neurologist and an expert on CBD’s benefits in treating epilepsy. Building on research he conducted with grants from the state of Florida and the Angelman Syndrome Foundation, Dr. Carney, together with Bobban Subhadra, Ph.D., a drug-discovery and product-development scientist, founded the Company in 2020 to create effective treatments for neurological disorders. The Company’s lead drug candidate, BIO017, is a cannabidiol (CBD) formulation designed to treat Angelman Syndrome (AS), a genetic, neurological disorder that results in development delays, speech and movement problems, sleep difficulties, and severe seizures. Biom therapeutics has recently applied for Orphan Drug Designation (ODD) for BIO017 from FDA.